TM
CRNX icon

Torren Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Torren Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$337 Hold
9
– – ﹤0.01% 889
2026
Q1 		$327 Sell
9
-14
-61% -$625 ﹤0.01% 921
2025
Q4 		$1.07K Buy
+23
New +$1.02K ﹤0.01% 1186

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Torren Management's CRNX Position: Q2 2026 in Review

Torren Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 9 shares worth $337. The position accounts for ﹤0.01% of the portfolio, ranked #889.

Torren Management first reported a position in CRNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.07K in Q4 2025. 100 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Torren Management held 9 shares of Crinetics Pharmaceuticals worth $337 as of Q2 2026.
  • Torren Management left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #889 holding.
  • Torren Management first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Crinetics Pharmaceuticals position peaked at $1.07K in Q4 2025.
  • 100 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.